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Abstract
The extracellular matrix (ECM) is a key interface between the cerebrovasculature and adjacent brain tissues.
Deregulation of the ECM contributes to a broad range of neurological disorders. However, despite this importance,
our understanding of the ECM composition remains very limited mainly due to difficulties in its isolation. To address this,
we developed an approach to extract the cerebrovascular ECM from mouse and human post-mortem normal brain
tissues. We then used mass spectrometry with off-line high-pH reversed-phase fractionation to increase the protein
detection. This identified more than 1000 proteins in the ECM-enriched fraction, with> 66% of the proteins being
common between the species. We report 147 core ECM proteins of the human brain vascular matrisome, including
collagens, laminins, fibronectin and nidogens. We next used network analysis to identify the connection between the
brain ECM proteins and cerebrovascular diseases. We found that genes related to cerebrovascular diseases, such as
COL4A1, COL4A2, VCAN and APOE were significantly enriched in the cerebrovascular ECM network. This provides
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unique mechanistic insight into cerebrovascular disease and potential drug targets. Overall, we provide a powerful
resource to study the functions of brain ECM and highlight a specific role for brain vascular ECM in cerebral
vascular disease.
Keywords
Cerebrovascular, proteome, extracellular matrix, basement membrane, matrisome
Received 29 January 2021; Revised 29 January 2021; Accepted 16 February 2021
Introduction
Brain function depends on the finely tuned interplay
and communication between cells within the neuro-
glial-vascular unit (NGVU), a dynamic structure com-
prised of endothelial cells, astrocytes and their end-feet
contacts, contractile cells (smooth muscle cells, peri-
cytes), neurons and microglia.1 The NGVU serves a
number of critical roles including cerebral blood flow
regulation, formation and maintenance of the blood-
brain barrier, controlling the exchange of substances
between blood and brain, immune surveillance and reg-
ulation of drainage mechanisms. The extracellular
matrix (ECM) proteins act as a complex meshwork
providing essential structural support and functional
stability within the NGVU. The protein components
within the ECM, collectively called the matrisome,
covers both core ECM proteins including glycopro-
teins, proteoglycans, glycosaminoglycans like
collagens, and ECM associated proteins, such as
ECM-modifying enzymes and ECM receptors.
The molecular composition of the ECM varies
among tissues and continuously undergoes remodelling
in both physiological and pathological states. Indeed,
deregulation of the ECM proteins and breakdown of
the NGVU underpin pathomolecular mechanisms in
ageing, cerebrovascular disease and dementia.2,3
Notably, mutations in ECM genes cause monogenic
forms of cerebrovascular disease.4–6 This includes
mutations in collagen IV, a key component of the spe-
cialised basement membrane in the ECM.7,8
Furthermore, common variants in genes that code for
ECM proteins are genetically associated with cerebral
small vessel disease and stroke.9–13 Thus, changes in the
composition of the ECM are likely to exert profound
effects on all NGVU components. Despite its critical
role in neurological disease, including cerebrovascular
disease, very little is known about the components of
the cerebrovascular ECM.
Biochemical analysis of the constituents of the ECM
is challenging due to their cross-linked structure and
insolubility. Advances in proteomics and mass-
spectrometry (MS) combined with bioinformatics are
unravelling the constituents of the ECM across many
healthy and disease tissues.14,15 However, there is lim-
ited information on the brain matrisome and particu-
larly that of the cerebrovasculature. To date most
information has been derived indirectly from proteo-
mic evaluation of the cerebrovasculature, including our
previous work which described the mouse cerebrovas-
cular proteome.16 This represents a significant
knowledge-gap that needs to be bridged to uncover
the mechanisms by which the ECM can affect cerebro-
vascular health.
In this study we characterise the proteome of the
cerebrovascular ECM in mouse and human brains.
We generate a new pipeline by combining our pub-
lished methodology to define the cerebrovascular pro-
teome16 with an experimental technique used to enrich
insoluble ECM proteins from the glomerulus.17 We
subsequently evaluate the human cerebrovascular
ECM proteome in relation to genetic susceptibility to




All animal experiments were conducted in accordance
with the Animal (Scientific Procedures) Act 1986, local
ethical approval at the University of Edinburgh, and
performed under appropriate personal and project
licences authority granted by the Home Office, and in
compliance with the ARRIVE guidelines for animal
research. C57BL/6J (wild-type, WT) mice were
obtained from Charles River (UK) and group housed
on a 12-hour light/dark cycle with ad libitum access to
food and water. A total of n¼ 3 adult male mice aged
4months were used in this study. Young adult brains
were used to avoid any confounding effects of age on
the vascular proteome. All tissues were collected at the
same time of day to avoid any differences due to circa-
dian rhythm.
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Human subjects
Brain tissue samples were taken from the basal ganglia
of n¼ 3 control subjects (male, aged 33, 34 and 39) in
the Edinburgh Sudden Death Brain Bank. The subjects
had no clinical or neuropathological evidence of a
chronic illness or neurological condition including cere-
bral vascular disease. The Edinburgh Sudden Death
Brain Bank has ethics approval from East of
Scotland Research Ethics Service (16/ES/0084) in line
with the Human Tissue (Scotland) Act.
Cerebral vessel enrichment
Mice were sacrificed under deep isoflurane anaesthesia
by transcardiac perfusion with heparinized phosphate
buffered saline. Brains were removed, sectioned into
left and right hemispheres and frozen in liquid nitro-
gen. Hemibrains were stored at 80C until processing.
Left hemispheres (hemibrains) were used for vessel and
subsequent ECM enrichment. Vessels were enriched
using modifications of our previously published proto-
cols.16,18 All steps were performed on ice or at 4 C to
avoid proteolysis. Briefly, human basal ganglia
(approx. 0.3-0.4g) and mouse hemibrains (approx.
0.2 g) were homogenised with 1mL ice-cold PBS
using a glass hand-held loose fit dounce homogeniser
with 20 strokes. Brain homogenates were then centri-
fuged at 250 g for 10min to remove cellular debris and
myelin. The pellets were re-suspended in 17.5% Ficoll
solution (Sigma) and centrifuged for 25min at 3,200 g
to separate brain vessels. This pellet was retained on
ice, whilst the supernatant was centrifuged again for
25min at 3,200 g. Pellets from both spins were com-
bined and re-suspended in 1mL 1% BSA-PBS. This
was further centrifuged for 10min at 2,000 g, the pellets
were washed in 1mL PBS (to remove BSA) and stored
at 80C, as the vessel enriched fraction, until further
processing.
Extracellular matrix enrichment
The ECM enrichment protocol was modified from.17
This method is used to remove intracellular proteins,
based on their solubility in detergent, and enrich for
ECM proteins, that are, in contrast, more insoluble,
reducing the complexity of protein samples for MS
analysis. In our modified protocol, pellets of vessel
enriched fractions were re-suspended in ice-cold
extraction buffer (5:1 vol/vol, 10mM Tris, 150mM
NaCl, 1% Triton-X-100, 25mM EDTA with added
protease and phosphatase inhibitors) to solubilise cel-
lular proteins. Samples were left on a rotator at 4 C
for 1 hour and then centrifuged at 14000 g for 10min.
The supernatant (Fraction A) was then removed and
stored at 4 C. The remaining pellet was re-suspended
in an ice-cold alkaline detergent buffer (5:1 vol/vol,
20mM NH4OH and triton X-100) to disrupt cell-to-
cell interactions, left on a rotator at 4 C for 1 hour
and centrifuged at 14000 g for 10minutes at 4 C and
the supernatant was collected as Fraction B. The
remaining pellet is then re-suspended in sample
buffer (5:1 vol/vol, 7% SDS, 30% glycerol, 200mM
Tris-HCl) to solubilise the ECM and to yield the final
ECM-enriched fraction. Fractions A and B were com-
bined to generate a cellular fraction. Proteins were
then prepared to a concentration of 20 mg for prote-
omic analysis.
SDS-PAGE and Western blotting
Protein levels for vessel enriched, ECM-enriched and
cellular fractions from mouse and human were deter-
mined using a Pierce BCA protein assay kit (Thermo
Scientific, UK). Samples were denatured at 70 C for
20min and resolved by SDS-PAGE. Proteins (8 mg)
were transferred to a PVDF membrane, blocked in
Odyssey Blocking Buffer in PBS (Licor, UK) and
incubated with primary antibodies diluted in
Odyssey Blocking Buffer and 0.1% PBS Tween over-
night at 4 C. Vessel enriched fractions were probed
with antibodies against blood vessel-associated pro-
teins (PECAM, occludin, SMA) to ascertain vessel
enrichment. ECM-derived fractions were probed
with antibodies against ECM (e.g. laminin, fibronec-
tin) and non-ECM components (eg. synaptophysin,
GAPDH) to ascertain ECM enrichment (antibodies
details are provided in Supplementary Table 1).
Membranes were washed in 0.1% PBS-Tween and
incubated for 1 hour at RT with species-specific fluo-
rescent dye-conjugated secondary antibodies diluted
in Odyssey Blocking Buffer and 0.1% PBS Tween.
Membranes were washed with 0.1% PBS-Tween and
imaged with the Odyssey CLx infrared imaging
system (LICOR Biosciences, Cambridge, UK).
Individual protein bands were normalised to the load-
ing control a-tubulin and subsequently fold differen-
ces expressed relative to either the total fraction or
ECM enriched fraction.
Proteomics sample preparation
Samples were prepared in a 96-well S-Trap plate
(Protifi LCC) as per manufacturer’s protocol. Briefly,
samples were reduced with 5ml 200mM DTT and alky-
lated with 20 ml 200mM IAM for 30min each, acidified
with 12% phosphoric acid 10:1 (v/v) sample to acid,
transferred into the S-Trap well and precipitated with 7
parts 90% methanol in 100mM TEAB to 1 part sample
(v/v). Samples were washed 3x by spinning the S-trap
plate at 1500xg for 30 s and the last step for 1min, each
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time with fresh 90% methanol in 100mM TEAB. The
sample was resuspended in 50 mL 50mM TEAB and
digested with 0.8 mg trypsin (Promega) overnight at
37 C. Peptides were eluted from the S-Trap by spin-
ning for 1min at 1500 g with 80 mL 50mM ammonium
bicarbonate, 80 mL 0.1% FA and finally 80 mL 50%
ACN, 0.1% FA. The eluates were dried down in a
vacuum centrifuge and resuspended in loading buffer
(2% ACN, 0.1% TFA) prior to off-line high-pH
reversed-phase fractionation (HpH fractionation) and
mass spectrometry (MS) acquisition.
Off-line high-pH reversed-phase fractionation on
agilent bravo assaymap
RP-S cartridges were primed with 100 mL ACN at
300 mL/min, equilibrated with 50 mL loading buffer
(2% ACN, 0.1% TFA) at 10 mL/min followed by load-
ing 120 mL sample (with a peptide content of about
18.5 mg) at 5 mL/min. the cartridge cup was washed
with 50 mL and an internal cartridge wash was per-
formed with 25 mL loading buffer at 5mL/min.
Each sample was divided into 8 fractions, which
were then run individually on the MS platform, to
determine how much additional depth arises from the
fractionated sample. The 8 fractions (elution steps)
were done with buffer A (Water, pH 10) and buffer B
(90% ACN, pH 10) at the following percentages of
buffer B: 5%, 10%, 12.5%, 15%, 20%, 22.5%, 25%
and 50%. The eluates of the following steps were
directly concatenated as 1þ 5, 2þ 6, 3þ 7 and 4þ 8.
Fractions were dried down in a vacuum centrifuge and
resuspended in loading buffer.
LC-MS/MS data acquisition
Peptides (50-80ng) were loaded onto Evotips as
described by the manufacturer. Briefly, Evotips were
activated by soaking them in isopropanol, primed
with 20 mL buffer B (ACN, 0.1% FA) by centrifugation
for 1min at 700 g. Tips were soaked in isopropanol for
1 s and equilibrated with 20 mL buffer A (water, 0.1%
FA) by centrifugation. Another 20 mL buffer A was
loaded onto the tips and the samples were added on
top of that. Tips were spun and then washed with 20 ml
buffer A followed by overlaying the C18 material in the
tips with 100 mL buffer A and a short 20 s spin.
Samples were run on a LC-MS system comprised of
an Evosep One LC and a Bruker timsTOF Pro.
Peptides were separated on an 8 cm analytical C18
column (Evosep, 3 mm beads, 100 mm ID) using the
pre-set 60 samples per day gradient on the Evosep
one. MS data acquisition was done in PASEF mode
(oTOF control v6.0.0.12). The ion mobility window
was set to 1/k0 start¼ 0.85 Vs/cm2 to 1/k0 end¼ 1.3
Vs/cm2, ramp time 100ms with locked duty cycle, mass
range 100 - 1700m/z. MS/MS were acquired in 4
PASEF frames (3 cycles overlap). For proteomics anal-
ysis, the raw data files were searched against either the
reviewed Uniprot homo sapiens databased (retrieved
2,01,80,131) or mus musculus (retrieved 2,01,90,304)
using MaxQuant19 version 1.6.10.43 and its built-in
contaminant database using tryptic specificity and
allowing two missed cleavages.
Downstream analysis of proteomics data
ECM proteins were identified and categorized in our
datasets based on the recently updated publicly avail-
able matrisome list (http://matrisome.org/20,21). The
Venn diagrams and bar plots were based on proteins
identified in two replicates with at least two unique
peptides. Most of the analysis (including Venn dia-
grams, differential expression, identification of poten-
tial ECM-interacting and disease-associated proteins)
was performed on datasets from which we filtered out
chromatin-associated, nuclear and mitochondrial pro-
teins using the genes from the respective terms of
BioPlanet and GO Biological Processes databases of
the Enrichr web server22 (http://amp.pharm.mssm.
edu/Enrichr/).
For comparison with published vascular proteome
datasets, proteins identified in the ECM and cellular
fractions in  two replicates were compared to either
the list of 5042 human proteins from retinal endothelial
cells (ECs) (reported with FDR  0.0123) or with
the list of 653 mouse vascular proteins identified in
 2 replicates.16
For the construction of protein-protein interactions
(PPI) network we used human proteins identified in at
least 2 replicates of the ECM-enriched fraction of HpH
fractionated samples. To identify proteins which might
interact with the ECM we used a 3-step filtering
approach. Firstly, we identified ECM-enriched pro-
teins with potential ECM location or function, based
on the available annotation, using databases of the
Enrichr web server (GO cellular component, GO
molecular function and Jensen compartment) and
GeneCards online database. Secondly, to narrow
down the list of potential ECM interactors, we com-
pared our list of ECM-enriched proteins with a list of
5137 potentially secreted human proteins, which were
identified using computational prediction algorithms.24
And lastly, we used the web servers SignalP 425 and
Phobius26 to further re-assess the list of potential
ECM-interactors for the presence of secreted or trans-
membrane domains.
ECM PPI networks were constructed using
StringApp in Cytoscape,27 by importing networks
from STRING database.28 We used networks with
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high confidence interactions, omitting proteins discon-
nected from the main network.
To analyse the potential relevance of the ECM PPI
network to cerebrovascular disease we next overlaid
the ECM PPI network with stroke, vascular dementia
and cerebral SVD-associated genes, which were
reported in published GWAS studies with P value 
1x107.9,29–32
Gene enrichment analyses with the open target
platform
As an additional approach, genes that are likely to be
causal in small vessel disease, stroke, Parkinson’s dis-
ease and Alzheimer’s disease were identified using the
‘Variant-to-Gene’ pipeline in the Open Target
Platform. Briefly, this pipeline takes into consider-
ation all genetics associations with P< 5e8 in the
GWAS Catalogue as well as UK biobank summary
statistics. To map genetic variants to genes, lead var-
iants are first used to identify tag variants through (i)
statistical fine mapping based on summary statistics
or (ii) linkage disequilibrium expansion.
Subsequently, these tag variants are integrated with
higher order genomic information such as quantita-
tive trait loci (expression QTLs,33 and protein
QTLs,34), chromatin interactions (promoter capture
Hi-C,35), in silico functional predictions36 and dis-
tance from the canonical transcript start site37 to gen-
erate variant-gene scores. Finally, aggregation of
variant-genes scores is carried out to identify likely
causal genes for the disease of interest.
Enrichment analyses for candidate causal genes in
the human cerebrovascular proteome and interacting
proteins, were carried out using a hypergeometric test
sampling at random (without replacement) from the
background containing annotated and non-annotated
genes. We also identified pathways that were signifi-
cantly enriched among disease causal genes, which
were overrepresented in the brain cerebrovascular
ECM, using the Reactome Knowledgebase.38 This
was based on pathways whose associate genes were
enriched among any overrepresented disease causal
gene using the Fisher’s exact test. All matrisome
genes were used as the background and the minimum
number of overlaps was set to 3. The P values were
adjusted for multiple testing by controlling the false
discovery rate (FDR). All enrichment analyses were
carried using the xEnricher functions in the R package
‘XGR’ (version 1.1.4).
Other statistical analysis
Western blot data were analysed using a non-
parametric Mann Whitney U test and a P value
below 0.05 was considered to be significant. For pro-
teomics analysis peptide and protein identifications are
reported by MaxQuant using the protein parsimony
principles39 and results were filtered to a 1% FDR.
At least one unique peptide was required to identify a
protein group. Protein quantification was performed
with the MaxLFQ algorithm within MaxQuant.40
The intensity and LFQ intensity columns of the
Maxquant output were used for protein identification
and quantification, respectively. The data were ana-
lysed in three samples (biological replicates) derived
from three individual mice or three patients.
Differential protein analysis was done using all pro-
teins, which were quantified in both ECM-enriched and
cellular fractions in at least two replicates, with at least
two unique peptides. The analysis of the differences in
protein levels between the ECM-enriched and cellular
fractions was done using limma package in R. We used
an empirical Bayes method for two group comparison
with the moderated t-test of the eb.fit function
output.41 The results were visualized on volcano plots
by plotting the false discovery rate (FDR) adjusted P
values for multiple-hypothesis testing with the
Benjamini–Hochberg method, with significance level
p  0.05 and absolute value of log2 fold changes,
log2fc  1. Additionally, we plotted on the volcano
plots the ECM markers quantified in the ECM-
enriched fraction in  two replicates, with  two
unique peptides, but present at zero levels in all 3 rep-
licates of the cellular fraction. The significance of the
enrichment of identified proteins in the vascular, adhe-
sion and disease proteins were calculated using the
hypergeometric test.
Results
Cerebral vessel and vascular ECM enrichment
Levels of cerebrovascular proteins were measured by
western blotting in vessel-enriched fractions and total
brain samples to confirm successful vessel enrichment.
The selection of protein markers was based on their
association with known cellular compartments of cere-
bral vessels including markers of vascular smooth
muscle (SMA), endothelial cells (PECAM), and tight
junctions (occludin). The data demonstrate that vascu-
lar proteins in the vessel-enriched fraction are markedly
enriched: with a 12- and 34-fold increase for SMA in
mouse and human tissues respectively (P< 0.05), an 11-
and 17-fold increase for PECAM in mouse and human
tissues respectively (P< 0.05) and a 6-fold increase for
occludin in mouse and human samples (P< 0.05)
(Figures 1(a) and (b), S1).
Using these vessel-enriched fractions from brain
tissue we then developed a fractionation approach to
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collect vessel-associated ECM proteins. Western blot-
ting confirmed enrichment of ECM proteins (3-fold
increase for fibronectin in mouse and human samples,
P< 0.05; 4- and 7-fold increase for laminin in mouse
and human samples respectively, P< 0.05). The effi-
ciency of the ECM enrichment was further confirmed
by measurement of synaptic (synaptophysin) and cyto-
plasmic (GAPDH) proteins. There was a profound
reduction in the levels of these proteins which were
barely detectable in the ECM-enriched fractions in
both mouse and human tissues (P< 0.05, Figures 1(c)
and (d), S2).
Following vascular ECM enrichment, samples were
analysed by mass spectrometry (MS) with and without
high-pH reversed-phase (HpH) fractionation to deter-
mine how much additional depth is obtained from the
fractionated sample. The proteomic workflow along
with a summary of results highlighting the total
number of proteins identified and quantified based on
one or two unique peptides is presented in Figure 2.
HpH fractionation of both ECM-enriched and cellular
fractions in mouse and human brain markedly
increased the number of identified proteins. In partic-
ular, in the ECM-enriched fraction, fractionation
resulted in a 3- and 3.2-fold increase in the number of
identified proteins for mouse and human samples,
respectively (Figure S3). The protein abundances were
linear between fractionated and non-fractionated pro-
teins, demonstrating that HpH fractionation did not
introduce any bias in protein level measurements
Figure S4). The protein levels also clustered together
on MA (“minus over average”) plots of fractionated
and non-fractionated samples, with no outlier proteins
(Figure S5).
Comparing the identified proteins in the
vascular ECM-enriched and cellular fractions with pre-
viously published vascular proteome datasets
indicated that most of our proteins were present
in these datasets. In particular, more than 73% of
human proteins identified in the ECM-enriched frac-
tion and more than 75% in the cellular fraction were
present in the vascular retinal proteome, consisting of
5042 endothelial cell (EC) proteins23; enrichment P val-
ue< 2.2·1016). The majority of the identified vascular
proteins (87% in ECM fraction) were common
between the ECM-enriched and cellular fractions
(Supplementary Table S2). Moreover, more than
90% of previously identified 653 vascular proteins
Figure 1. Cerebrovascular enrichment, extracellular matrix enrichment and validation in mouse and human brain. a. vessel-enriched
fraction was generated from a total brain homogenate in mouse and human brain and validated by increased levels of vascular-related
proteins; smooth muscle actin (SMA), (PECAM (endothelial cells) and occludin (tight junction protein) compared to total brain
homogenates (antibodies details are in Supplementary Table S1). b. Measurement of protein levels in mouse and human (n¼ 3) total
and vessel-enriched fractions highlights the marked increase in these proteins in the vessel-enriched fractions compared to total brain.
c. Following vessel-enrichment, subsequent fractionation generated cellular and ECM-enriched fractions. d. ECM-enrichment was
validated by increased levels of ECM-associated proteins (laminin, fibronectin) and reduced levels of synaptic and cytoplasmic proteins
(synaptophysin, GAPDH) compared to cellular fractions. a-tubulin is shown as the loading control (a,c) and to which protein bands are
normalised and then expressed as fold change to total protein (b) or ECM enriched (d).
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from mouse brain16 was present in either ECM-
enriched or cellular fractions of our mouse samples
(Supplementary Table S2), further confirming the vas-
cular enrichment.
Identification of cerebrovascular matrisome related
proteins
Since HpH fractionation substantially increased the
yield of proteins, this approach was subsequently
used to identify and quantify proteins in both the
ECM-enriched and cellular fractions of mouse and
human vasculature from three biological replicates.
Based on data acquired on two replicates, MS identi-
fied 575 proteins in the ECM-enriched samples and
2820 proteins in the soluble or cellular fraction from
mouse samples, and 1168 proteins in the ECM-
enriched samples and 2614 in the soluble or cellular
fraction from human tissues, (Figure S6;
Supplementary Table S3). While a number of proteins
found in the ECM-enriched samples were also found in
the cellular fraction, many were detected at significant-
ly different levels, as demonstrated by differential
expression analysis below.
The previously published matrisome list was used
to annotate known ECM and ECM-associated pro-
teins found in our samples (Figure 2 20,21). We found
that a total of 103 out of 2890 of the proteins
identified in our mouse samples were annotated as
matrisome proteins and 114 out of 2952 in human
samples (Figure 3(a) and (b); Supplementary Table
S4). More specifically, in the ECM-enriched fraction,
52 out of 575 proteins detected in the ECM-enriched
samples from mouse tissues and 80 of the 1168 pro-
teins detected in the ECM-enriched samples from
human tissues were annotated as matrisome proteins
(Figure 3(a) and (b), Table 1). The cerebrovascular
ECM proteins include 10 mouse and 11 human colla-
gens; 26 mouse and 36 human glycoproteins; and 5
mouse and 6 human proteoglycans. Notably, a sub-
stantial number of identified ECM proteins (19 for
mouse and 20 for human) were basement membrane
proteins (Table 114). Furthermore, 59 of the identified
ECM proteins were shared between species (encoded
by orthologous genes; Figure 3(c)). Approximately
half of them (52-54% in mouse and human) were
core matrisome proteins, comprised mostly of glyco-
proteins, with the most abundant ECM-enriched pro-
teins being fibronectins, collagens, laminins and
nidogens, of which the last three are core basement
membrane components (Figure 3(d) to (f);
Supplementary Table S4). The largest sub-group of
the remainder were ECM-affiliated proteins, such as
lectins or annexins - known secreted proteins that
associate with the solid-phase.
Figure 2. Proteomic workflow, numbers of proteins identified and quantified. Workflow, left, shows steps by which mouse and
human vessel enriched brain tissue is then ECM enriched and cellular extracts generated. Subsequent to this, proteins are identified
and quantified with and without HpH fractionation using MS and undergo downstream analysis. The numbers shown on right are
based on 2 biological replicates and shown for ECM-enriched and cellular fractions, described in “Extracellular matrix enrichment”
section of Materials and Methods. MS proteins were identified and quantified using MaxQuant as described in Materials and Methods.
The numbers calculated for MS samples with or without pre-fractionation are shown by bold and normal fonts, respectively.
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Differential protein analysis of cerebrovascular
ECM-enriched and cellular fractions
89% of mouse ECM-enriched proteins and 71% of
human ECM-enriched proteins were also detected in
their counterpart cellular fraction (Supplementary
Table S3). To explore the differences in protein levels
between the ECM-enriched and cellular fractions, dif-
ferential expression analysis of the proteins was per-
formed, using 189 mouse and 356 human proteins
quantified in both HpH-fractionated samples in at
least 2 replicates, with at least 2 unique peptides
(Supplementary Table S5).
The respective volcano plots of differentially
expressed fractionated proteins (FDR  0.05, fold
change  2) show that for 180 human proteins their
protein levels were significantly different between the
ECM-enriched and cellular fractions (Figure 3(g)
and (h)). This includes 21 known human ECM proteins
(coloured by blue, Figure 3(g) and (h)), such as the key
ECM constituents COL6A1, COL6A3, COL12A1,
LAMA2, LAMA4, LAMA5, LAMB2 and LAMC1.
In addition, another 16 known ECM proteins were pre-
sent exclusively in the ECM-enriched fraction, such as
COL1A1, COL1A2, COL4A1, COL15A1, COL18A1,
EMILIN1, LAMA3 and LAMC3 (shown as columns
on the right, Figure 3(g) and (h)). In mouse samples,
there were 128 differentially expressed proteins, with 13
of them being known ECM proteins. Another 12 ECM
proteins were exclusively present in the ECM-enriched
Figure 3. Protein classes in brain vascular ECM and cellular fractions. a–f. Number of ECM proteins annotated with MatrisomeDB.
Venn diagrams correspond to the mouse (a) or human (b) ECM proteins identified in ECM-enriched and cellular fractions in at least 2
biological replicates. c. The overlap between orthologous mouse and human ECM proteins. (d–f) The pie charts show total numbers
of identified ECM proteins grouped by matrisome categories corresponding to a–c. Two main categories are core matrisome and
matrisome associated protein, each subdivided into 3 subgroups (collagens, ECM glycoproteins, proteoglycans and ECM affiliated,
ECM regulators and secreted factors, respectively14). g,h. Volcano plots for proteins differentially expressed between ECM-enriched
and cellular fractions in HpH fractionated samples. Proteins quantified in at least 2 biological replicates were used for this analysis.
Proteins with significantly differential expression (FDR  0.05) are marked in blue. ECM proteins quantified exclusively in the ECM
fraction are listed on the right.
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Table 1. Matrisome proteins identified in ECM-enriched fraction of mouse and human samples in at least 2 biological replicates.
Matrisome categories of the core matrisome and matrisome-associated groups are indicated by the colours. Averaged intensities are
shown together with the gene names of the identified proteins. Gene encoding basement membrane proteins are shown by bold.
Core matrisome Core matrisome
Mouse Human Mouse Human
Gene Intensity Gene Intensity Gene Intensity Gene Intensity
Collagens ECM glycoproteins
Col4a2 8.7Eþ 06 COL4A2 2.0Eþ 07 DSP 9.4Eþ 04
Col1a1 4.7Eþ 06 COL6A3 9.5Eþ 06 EFEMP1 8.2Eþ 04
Col6a3 2.1Eþ 06 COL1A2 6.6Eþ 06 LGI3 6.6Eþ 04
Col6a1 1.3Eþ 06 COL6A1 3.0Eþ 06 TGFBI 3.5Eþ 04
Col18a1 1.2Eþ 06 COL4A1 2.5Eþ 06 PXN 3.0Eþ 04
Col1a2 5.9Eþ 05 COL1A1 2.3Eþ 06 LTBP1 2.3Eþ 04
Col4a1 4.8Eþ 05 COL18A1 2.0Eþ 06 MATN2 2.2Eþ 04
Col6a2 4.8Eþ 05 COL12A1 9.2Eþ 05 EDIL3 2.6Eþ 03
Col12a1 2.1Eþ 05 COL15A1 4.3Eþ 05 Proteoglycans
Col15a1 1.4Eþ 05 COL14A1 1.7Eþ 05 Dcn 5.2Eþ 04 HSPG2 2.2Eþ 07
COL4A6 6.8Eþ 04 Bgn 3.8Eþ 04 HAPLN2 5.5Eþ 05
ECM glycoproteins Prelp 2.5Eþ 04 BGN 3.9Eþ 05
Lamc1 3.2Eþ 07 LAMB2 4.4Eþ 07 Hapln1 2.1Eþ 04 DCN 3.8Eþ 05
Lamb2 3.2Eþ 07 LAMC1 3.2Eþ 07 Ncan 1.2Eþ 04 VCAN 8.1Eþ 04
Lama5 1.1Eþ 07 LAMA5 1.5Eþ 07 PRELP 6.1Eþ 04
Nid1 1.0Eþ 07 NID1 1.3Eþ 07 Matrisome-associated
Agrn 7.8Eþ 06 LAMA2 1.3Eþ 07 Mouse Human
Tinagl1 5.3Eþ 06 AGRN 1.2Eþ 07 Gene Intensity Gene Intensity
Nid2 5.2Eþ 06 FN1 9.1Eþ 06 ECM-affiliated proteins
Lama2 4.4Eþ 06 NID2 8.7Eþ 06 Gpc5 6.2Eþ 04 ANXA1 7.8Eþ 05
Lama1 3.3Eþ 06 TINAGL1 8.5Eþ 06 Sdc4 5.7Eþ 04 LGALS9 2.2Eþ 05
Vwa1 2.5Eþ 06 FGG 7.2Eþ 06 Gpc4 2.6Eþ 04 LGALS1 4.7Eþ 04
Lama4 2.0Eþ 06 FGA 2.1Eþ 06 Gpc1 9.2Eþ 03 ANXA6 3.6Eþ 04
Lamb1 1.4Eþ 06 LAMA1 1.8Eþ 06 Anxa2 8.1Eþ 03 ANXA5 3.1Eþ 04
Vwf 1.4Eþ 05 LAMA4 1.5Eþ 06 ANXA2 2.7Eþ 04
Lamc3 9.8Eþ 04 VWA1 1.2Eþ 06 ANXA7 6.2Eþ 03
Tnr 8.5Eþ 04 EMILIN1 9.7Eþ 05 ECM regulators
Lama3 7.9Eþ 04 LAMC3 8.2Eþ 05 Itih5 9.2Eþ 05 TGM2 4.2Eþ 06
Mmrn2 5.1Eþ 04 VWA7 7.7Eþ 05 Tgm2 6.0Eþ 05 CTSD 1.1Eþ 06
Ltbp4 4.9Eþ 04 ELN 7.3Eþ 05 Gm5409 3.0Eþ 05 CAP2 3.7Eþ 05
Emilin1 4.4Eþ 04 LAMB1 7.0Eþ 05 Serpinh1 1.1Eþ 05 SERPINH1 1.1Eþ 05
Dsp 4.3Eþ 04 VWF 5.6Eþ 05 TIMP3 3.2Eþ 05
Vtn 2.8Eþ 04 TNXB 4.5Eþ 05 PLAT 1.1Eþ 05
Papln 2.2Eþ 04 MMRN2 4.1Eþ 05 HTRA1 5.7Eþ 04
Fbln5 1.7Eþ 04 FBN1 3.5Eþ 05 Secreted factors
Lgi3 1.6Eþ 04 TNR 3.1Eþ 05 Sart1 8.4Eþ 04 PC 1.9Eþ 06
Lgi1 1.1Eþ 04 SBSPON 1.5Eþ 05 LMNB2 1.0Eþ 06
Sbspon 5.8Eþ 03 LAMA3 1.5Eþ 05 MLF2 2.2Eþ 05
Mfap1 8.2Eþ 04 PAPLN 1.1Eþ 05 NBN 1.3Eþ 05
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fraction (Figure 3(g) and (h)). As expected, there was a
substantial reduction in the numbers of proteins that
were differentially expressed between these fractions
when samples were not HpH fractionated prior to
MS, with 39 and 28 proteins in human and mouse,
respectively (Figure S7, Supplementary Table S5).
Identification of cerebrovascular proteins that
potentially interact with the ECM
To identify potential ECM-interacting proteins not
previously annotated as matrisome proteins, we used
all proteins identified with  2-fold higher average
levels in ECM-enriched compared to cellular fraction
or uniquely expressed in at least two replicates in the
ECM-enriched fraction. 337 proteins (Supplementary
Table S6) were detected in the ECM-enriched fraction
of human samples, but not annotated as being part of
the matrisome. Based on previously annotated protein
subcellular location and function, 50 of these proteins
were identified as potential candidates for interaction
with brain ECM (Supplementary Table S6).
Comparison of the identified 50 proteins with the
reported list of 2412 proteins involved in cell adhesion
(so-called “adhesome”42) confirmed significant enrich-
ment in adhesion proteins (P value< 1.2·106). We
next assessed the 50 ECM-enriched proteins for the
presence of secreted or transmembrane domains24–26
and identified 11 proteins that were putatively secreted
or had signal peptides or transmembrane domains
(Supplementary Table S7). Network analysis with
STRING was undertaken on these 11 proteins and
the 80 Matrisome proteins identified in the ECM-
enriched fraction. The resulting PPI network revealed
that 7 of these predicted ECM-interacting proteins
(coloured in orange on Figure 4) were connected to
known ECM proteins.
Genes relevant to cerebrovascular disease are
enriched in the brain ECM-interacting proteins
To explore whether the constructed ECM network of
Figure 4 has relevance to cerebrovascular disease, we
overlaid the network with the disease-associated genes
Figure 4. Network of interactions between known ECM proteins and predicted ECM-interacting proteins. The network comprises
proteins either  2-fold enriched or exclusively present in the ECM fraction. 7 predicted ECM-interacting proteins are not annotated
as part of the matrisome and predicted to have signal peptides or extracellular domains. Previously established ECM proteins
identified by Matrisome DB, as well as predicted ECM-interactors are coloured as indicated. The networks were built using the
STRING database with a high confidence of interactions.
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reported in published GWAS studies on stroke,29,30
vascular dementia (VaD31,32) and cerebral SVD.9 We
found that this network was significantly enriched
(P value 7104) with the cerebrovascular disease-
associated genes (Figure 5(a); Supplementary Table
S7). There were 17 disease genes directly connected to
the ECM network, with several genes (COL4A1,
COL4A2, VCAN, FGA, MMP12) representing the
main hubs across the brain vascular matrisome.
Interestingly, APOE, a key regulator of BBB and cere-
brovascular integrity43 and one of the biggest genetic
risk factors for dementia, is highly connected to this
network.
As a complementary approach, we compiled a list of
likely causal genes in ischemic stroke, cerebral SVD,
Alzheimer’s disease and Parkinson’s disease based on
the ‘Variant-to-Gene’ pipeline within the Open Target
Platform (Supplementary Table S8). Notably, we found
a significant enrichment of genes relevant to cerebrovas-
cular disease among genes that code for ECM and inter-
acting proteins (stroke: number of overlapping
genes¼ 21, FDR¼ 0.011; SVD: number of overlapping
Figure 5. Disease genes and pathways in the human brain vascular ECM network. a. PPI network of cerebrovascular disease-
associated genes (stroke, SVD and vascular dementia) connected to the ECM network of Figure 4. b. The overlap between brain
disease genes (based on Open Target Platform) and ECM-related gene sets. PD¼ Parkinson’s disease, AD¼ Alzheimer’s disease,
CSVD¼ cerebral small vessel disease, Stroke¼ ischemic stroke, ‘brain ECM network’ is the ECM network with interacting genes on
STRING, ‘core matrisome’ and ‘matrisome associated’ are matrisome genes.14 The bubble size represents the number of overlapping
genes. Significant results from brain ECM network are labelled. c. Enriched pathways amongst stroke and CSVD genes, overlapping
with the brain ECM network. The vertical line is the FDR cut-off at 0.05.
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genes¼ 11, FDR¼ 0.04) (Figure 5(b) and
Supplementary Table S8). Interestingly, we did not find
any enrichment of genes relevant to Alzheimer’s disease
(number of overlapping genes¼ 57, FDR¼ 0.68) and
Parkinson’s disease (number of overlapping genes¼ 37,
FDR¼ 0.19); supporting a possible specific role for
ECM and interacting proteins in cerebrovascular disease.
The 21 ischemic stroke genes overlapping with genes
that code for ECM-related proteins (Supplementary
Table S8) included COL3A, MMP1, MMP12 and
MMP3. We next carried out pathway enrichment anal-
yses to provide biological insight into this overlap,
using the Reactome Knowledgebase.38 We identified
several key pathways that were significantly enriched
(Figure 5(c) and Supplementary Table S8). These
included formation of fibrin clot (fold change¼ 18.7,
5.00E-08), integrin cell surface interactions (fold
change¼ 9.25, FDR¼ 0.000038) and degradation of
the extracellular matrix (fold change¼ 11.7, FDR¼
0.000039). Furthermore, the 11 enriched cerebral
small vessel genes overlapped with genes that code
for brain ECM-related constituents included APOE,
COL4A, COL4A2 and COLGALT1 and were signifi-
cantly enriched in several informative pathways
(Figure 5(c) and Supplementary Table S8). The key
pathways included NCAM1 interactions (fold change-
¼ 11.5, FDR¼ 0.00018) and Collagen formation (fold
change¼ 9.32, FDR¼ 0.00027).
Discussion
ECM deregulation is emerging as a common contribu-
tory, and sometimes causal, mechanism in cerebrovas-
cular disease.2,3 However, very little is known about the
composition of the cerebrovascular ECM due to its
complexity and insolubility which has significantly hin-
dered its biochemical and molecular analysis. Here we
report an efficient method to extract and analyse cere-
brovascular ECM proteins which can be used as a plat-
form to establish for the first time, the proteome of
mouse and human cerebrovascular ECM in normal
brain tissues. We then used network analysis to explore
the connection between the identified ECM proteins
and proteins which are known to be involved in cere-
brovascular disease. Interestingly, we found that genes
relevant to cerebrovascular disease including ischemic
stroke and cerebral SVD are exclusively overrepresent-
ed among genes that code for brain ECM and interact-
ing proteins.
The method that we outline is based on cerebral
vessel extraction, separation of cellular and ECM-
enriched fractions based on their solubility, followed
by off-line high-pH reversed-phase fractionation to
increase protein detection by MS. Our approach suc-
cessfully enriched for ECM proteins and the HpH
fractionation step results in 3.5–3.9 fold increase in
proteome depth, which highlights the complexity of
pre-fractionated samples. The ECM-enriched proteins
include collagens I and VI, main constituents of the
brain ECM, with considerable enrichment of major
basement membrane proteins collagen IV and laminins
(Figure 3(g) and (h)). Furthermore, many ECM pro-
teins that we discovered as constituting the human
brain vascular matrisome are annotated matrisome
proteins (Naba et al., 2012 and 2016). There was also
significant overlap with proteins identified from the
retinal vascular proteome (Smith et al., 2018), mouse
cerebrovascular proteome (Searcy et al., 2014) and the
adhesome (Horton et al., 2015).
A large proportion of proteins identified in the
ECM-enriched fractions, but not previously annotated
as being part of the matrisome, include intracellular
insoluble proteins, such as chromatin-bound and cyto-
skeleton components. After removing these likely con-
taminants, the remainder may represent putative
secreted factors, transmembrane proteins or adhesion
molecules based upon our enrichment analysis.
Importantly we found 7 proteins, present in our sam-
ples, are connected to the network of matrisome pro-
teins. These include BCAM and PARVB, which are
involved in cell adhesion and migration. The network
also includes VE-Cadherin (CDH5) and vascular endo-
thelial growth factor VEGFR1 (FLT1), both of which
play an important role in angiogenesis and vasculogen-
esis. Further studies of these proteins might uncover
their potential involvement in regulating normal and
pathological states of the vascular ECM.
We found that many proteins, identified by MS,
were present in both ECM-enriched and cellular frac-
tions. This is perhaps not unexpected since the cells of
the NVGU will generate these proteins for secretion
and incorporation into the ECM. It will be interesting
to understand from future studies how much of disease
associated changes in the matrisome are captured by
the soluble fraction given the considerable overlap we
found between fractions. Comparisons between these
fractions might also give important insights into dis-
ease induced changes that exclusively occur outside
the cells. Our data also demonstrated a significant
overlap between mouse and human brain ECM sam-
ples, with 70% of all identified human protein and 66%
of human ECM markers present in mouse samples.
This gives confidence in the murine models to study
disease and other processes that might affect the
brain matrisome. It was noted that there were fewer
proteins identified in the mouse compared to the
human ECM proteome (Table 1). This may be due to
technical reasons related to differences in the initial
weight of the tissues used to generate vascular and sub-
sequent ECM enriched fractions. The starting material
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of the mouse brain tissue (approx. 0.2 g) was smaller
than the human brain tissue (0.3-0.4g), potentially lead-
ing to a greater enrichment of the vasculature and
then ECM in human compared to mouse samples
(Figure 1).
There are several potential limitations of our study.
Firstly, our preparations were done using the whole
brain vasculature, consisting of different vascular seg-
ments. Therefore, our study can be considered as a
first, global characterization of the cerebrovascular
ECM proteome. Further developments of the vascular
dissection methods might allow analysis of more spe-
cific vascular regions. Secondly, our cellular fractions
represent a mixture of different cell types that are pre-
sent in the cerebrovasculature. Therefore, the proteins
identified in the cellular fractions originate from differ-
ent cell types. Thirdly, similar to previously used meth-
ods of ECM enrichment, our method might extract
contaminating insoluble constituents from nucleus,
mitochondria and other intracellular compartments.
While we filtered out those potentially contaminating
proteins from the ECM fractions, our data might still
include some proportion of poorly annotated proteins,
originating from these insoluble constituents. Finally
future studies are required to assess directly the effect
of disorders such as SVD or vascular dementia have
on the vascular ECM. Our studies have served to
highlight that proteins relevant to these diseases are
present in the network and it will be interesting to
investigate whether these are dysregulated in patholog-
ical states.
To explore the potential pathogenicity of the ECM,
we built the PPI network linking the ECM proteins,
identified in our samples, to the proteins encoded by
candidate GWAS genes associated with cerebrovascu-
lar diseases (Figure 5(a)). In addition, we used Open
Target Platform to further evaluate the relevance of
our ECM network to neurologic disease. Both
approaches demonstrate the significant overlap
between the ECM-related genes and cerebrovascular
disease genes. The differences in the overlapping gene
sets (Figure 5(a), Table S8) were mainly due to different
strategies to prioritize the genes (based on GWAS
alone, or in combination with other types of relevant
information, such as QTLs, chromatin interactions and
in silico functional predictions). Interestingly, the over-
lap between the ECM-related genes and genes associ-
ated with general neurologic diseases (Parkinson’s or
Alzheimer’s disease) was not significant. Therefore, by
using proteomics of ECM-enriched healthy brain tis-
sues and network analysis we found that the brain
ECM network is specifically connected to cerebrovas-
cular disease genes.
Recent studies have also implicated cerebrovascular
ECM proteins in mechanisms of other relevant
pathological processes including paediatric stroke,44
hypertension,45 and disruption of the blood brain bar-
rier (BBB).2,46 It has been shown that increased levels
of collagens (e.g., COL4A1) might be conducive to
stroke by increasing the stiffness of cerebral arteries,
leading to hypoperfusion and hypertension.45
Cerebral hypoperfusion is also known to be associated
with microvascular inflammation including dysfunc-
tion of endothelial cells and activation of microglia
which release metalloproteinases leading to BBB dis-
ruption in SVD and other cerebrovascular diseases.2
In line with these studies our ECM-related disease net-
work includes genes involved in structural stability
(e.g., collagens), adhesion, ECM remodelling (e.g.,
MMP1, MMP3, MMP12), angiogenesis and activation
of CNS inflammation. Interestingly, APOE is highly
connected to this network, including to metalloprotei-
nases and fibrinogens and previous studies have indi-
cated APOE is an important regulator of
cerebrovascular integrity,43,47 highlighting the potential
importance of this disease gene in remodelling of the
brain vascular matrisome.
It is worth noting that although the present study
did not investigate gender effects, some gender-related
differences in the microvascular proteome48 might con-
tribute to cerebrovascular pathology. These
gender effects are largely related to mitochondrial
metabolism and its ECM regulators, such as annex-
ins,48 which might be explored in future studies.
Another important factor to be considered for future
disease-related studies is age, a major risk factor for
SVD and cerebrovascular disease, affecting
disease severity and outcome, including post-stroke
remodelling of the brain tissues.49 We previously dem-
onstrated an age-dependent impact on the cerebrovas-
cular proteome in mice.16 Age also modifies axonal
regeneration, a process depending on cellular interac-
tions with the ECM, migration and angiogenesis and
mediated by multiple signalling molecules, such as
BDNF, VEGF and TGF-b.49 In support of such a
role, our pathway analysis of the ECM-related disease
genes demonstrated enrichment with processes such as
neurite growth, axon guidance, integrin signalling and
ECM degradation.
In conclusion, we present a refined method for effi-
cient enrichment of the mouse and human brain matri-
some associated with the cerebrovasculature. The
human brain vascular matrisome and its interacting
proteins are enriched in proteins implicated in cerebro-
vascular disease, suggesting that the brain matrisome
has a key role in pathogenic mechanisms. Our method
of cerebrovascular ECM enrichment can be further
applied to various pathological conditions and our
data represent a useful resource for exploration of the
cerebrovascular matrisome.
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